Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 45

  • 1 389 clinical trials
  • 585 recruiting
  • 453 conditions
  • 29 countries

Conditions in this area

453 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis43Glioblastoma40Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Cognitive disorder18Epilepsy18Giant cell arteritis18Partial seizures18Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Anaesthesia16Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+429

Clinical trials in Nervous system disorders

1 389 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 389 clinical trials

Duchenne muscular dystrophy

Recruiting

Study on the Safety and Effects of SQY51 for Children and Adults with Duchenne Muscular Dystrophy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Sqy51
  • Sponsor:Sqy Therapeutics

Diabetic foot infection

Recruiting

Study on the Safety and Effectiveness of Contezolid Acefosamil, Contezolid, and Linezolid for Adults with Moderate or Severe Diabetic Foot Infections

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Aztreonam
  • Sponsor:Micurx Pharmaceuticals Inc.

Neuralgia

Recruiting

Study on the Effects of THC 2% Oil for Patients with Chronic Neuropathic Pain

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Dronabinol
  • Sponsor:Centre for Human Drug Research

Migraine without aura

Recruiting

Study on the Effectiveness of High-Flow Oxygen Therapy for Migraine Attacks in Emergency Department Patients

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Oxygen
  • Sponsor:Centre Hospitalier Universitaire De Nice

Glioma

Recruiting

Study on Fluorodopa (18F) for Diagnosing Low-Grade Glioma in Patients Without MRI Contrast Enhancement

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorodopa (18F)
  • Sponsor:CHRU De Nancy

Malignant glioma

Recruiting

Study of ONC201 for Patients with Newly Diagnosed H3 K27M-mutant Diffuse Glioma After Radiotherapy

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:2,4,6,7,8,9-Hexahydro-4-((2-Methylphenyl)Methyl)-7-(Phenylmethyl)Imidazo(1,2-A)Pyrido(3,4-E)Pyrimidin-5(1H)-One
  • Sponsor:Chimerix Inc.

Cerebrovascular accident

Recruiting

Study on Tranexamic Acid and Sodium Chloride for Patients with Stroke-Related Brain Bleeding

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:University Of Nottingham

Glioblastoma

Recruiting

Study of Debio 0123 and Temozolomide for Adults with Recurrent or Newly Diagnosed Glioblastoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sulfamethoxazole
  • Sponsor:Debiopharm International SA

Brain neoplasm

Recruiting

Study on Lithium Sulphate to Prevent Cognitive Impairment in Children After Brain Tumor Radiotherapy

Registered drug
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:Lithium Sulphate, Anhydrous
  • Sponsor:Karolinska University Hospital

Neuroblastoma

Recruiting

Study of Lutetium (177Lu) Oxodotreotide for Children with Relapsed or Refractory High-Risk Neuroblastoma

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:Edotreotide
  • Sponsor:Karolinska University Hospital

Partial seizures

Recruiting

Study on the Effects of Azetukalner in Patients with Focal-Onset Seizures

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Amyotrophic lateral sclerosis

Recruiting

Study on the Effects of Rituximab for Patients with Amyotrophic Lateral Sclerosis (ALS)

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Paracetamol
  • Sponsor:Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride72 clinical trialsTemozolomide37 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide25 clinical trialsParacetamol24 clinical trialsCarboplatin15 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.